Copyright
©The Author(s) 2026. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Feb 7, 2026; 32(5): 113693
Published online Feb 7, 2026. doi: 10.3748/wjg.v32.i5.113693
Published online Feb 7, 2026. doi: 10.3748/wjg.v32.i5.113693
Mac-2 binding protein glycosylation isomer as a novel serum biomarker for recurrence in hepatocellular carcinoma
Kyle R Stephens, Megan Wilson, Robert C G Martin II, Division of Surgical Oncology, Hiram C Polk Jr, MD, Department of Surgery, University of Louisville, Louisville, KY 40202, United States
Manting Xu, Department of Radiology, University of Louisville, Louisville, KY 40202, United States
Jeremy T Gaskins, Department of Bioinformatics and Biostatistics, University of Louisville, Louisville, KY 40202, United States
Gina Genova, Kornhauser Health Sciences Library, University of Louisville, Louisville, KY 40202, United States
Co-first authors: Kyle R Stephens and Megan Wilson.
Author contributions: Stephens KR and Wilson M are co-first authors, and contributed equally to study conception, protocol design, data extraction, and drafting of the manuscript. Martin II RCG is the corresponding author who supervised the study, provided critical revisions, and is responsible for the overall integrity of the work as the corresponding author. Gaskins JT conducted the statistical analyses, generated the figures, and contributed to interpretation of the data. Genova G designed and executed the systematic search strategy across all databases and assisted with reference management. Xu M assisted with screening of articles, data verification, and formatting of figures and tables. All authors reviewed and approved the final manuscript.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Robert C G Martin II, MD, PhD, Division of Surgical Oncology, Hiram C Polk Jr, MD, Department of Surgery, University of Louisville, 315 E Broadway, Louisville, KY 40202, United States. robert.martin@louisville.edu
Received: September 1, 2025
Revised: October 31, 2025
Accepted: December 22, 2025
Published online: February 7, 2026
Processing time: 149 Days and 20.5 Hours
Revised: October 31, 2025
Accepted: December 22, 2025
Published online: February 7, 2026
Processing time: 149 Days and 20.5 Hours
Core Tip
Core Tip: Predicting tumor recurrence following curative treatment for hepatocellular carcinoma (HCC) remains a cha